A newly established family office based in the USA seeks to leverage its technology expertise (i.e. AI, machine learning, cloud computing, cybersecurity, etc.) and invest in innovative early-stage healthcare companies that integrate technology, has the potential to become highly disruptive, and improve quality of life. To date, the firm has invested in 3 healthcare companies and continues to grow their portfolio. Currently, the firm is focused on pre-seed to seed funding with initial check size ranging from $100-250K, and up to $1M over the lifetime of the investment. The firm has a large footprint in North America and Israel, and will consider investment opportunities globally.

The firm is most interested in companies that are developing novel solutions to healthcare through the use of technology. The firm will consider medical technology companies, given that there is a strong data or technology component. Areas of high interest include the use of AI in drug discovery, drug delivery applications, SaaS/enterprise solutions in healthcare services, etc. At this time, the firm is not interested in biotech therapeutics or B2C applications.

The firm does not have specific company or management team requirements, but having an experienced management team with a track record of success is a huge plus. The firm typically co-invests alongside larger VC firms, but is open to leading rounds as well depending on the stage of the company and the firm’s capacity to contribute as a value-add. The firm does not always seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A holding company headquartered in USA and China with additional offices in throughout China aims to serve human healthcare and technological development through high-tech investment and real estate investment. Through its investment arm, the firm makes venture investments in healthcare. Typical allocations range from $1-10M in companies from Seed to Series B stages. The firm is open to leading or following in a round. The firm is looking for opportunities from US and Canada that have a China angle.

Additionally, while investing, the firm seeks to leverage their real estate resources in China while investing in companies. This could be through the establishment of a manufacturing plant in China or even starting a joint venture office in China.

Within healthcare, the firm considers biopharmaceuticals, medical devices, diagnostics, and AR/VR/AI innovations in healthcare. The firm is focused on diseases with large market potential including oncology, infectious disease, diabetes, CNS, and cardiovascular diseases. The firm is opportunistic in terms of stage of development and typically participates in Seed to Series B rounds.

The firm is seeking innovative products and can aid with management, operations, and registration. Leveraging its resources in China, the firm can facilitate distribution in the China market. However, distribution rights are not a requirement for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA investment office of a biotech incubator sector fund headquartered in China currently manages two venture funds including an RMB fund I and a USD fund II. The firm can allocate from $200,000 to $800,000 of equity capital in seed round companies and can make investments ranging from $1 to $10 million in series A companies. The firm looks to tailor its incubator and CRO services to the needs of its partners, helping them to reach key value-added milestones. The firm will consider opportunities based in China and North America, companies within a strong China angle involvement is their sweet spot. The firm is actively seeking in-licensing opportunities and plans to make 10-12 investments next year but is flexible.

The firm focuses mostly on therapeutics, while the firm is also open to Diagnostics. The firm can utilize its CRO services to advance portfolio company’s products into or through clinical trials. The firm is currently most interested in small molecule first-in-class drugs. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications. For therapeutics, the firm is looking to invest in pre-clinical stage. For diagnostics, the firm will consider companies from in-development to clinical stages. The firm will not invest in Medical Devices Healthcare IT companies.

The firm looks to act as a lead investor in seed round investments and can participate as either lead or co-investor in series A investments. The firm is looking for companies with skilled and experienced management teams. The firm prefers to support companies that own exclusive IP protection with renowned universities or research institutions. The firm also prefers to work with companies that have a technical expert and experienced in clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm founded in 2003 with headquarters in the USA has previously invested in real estate, retail, and consumer products industries. However, the firm has recently focused on life science investment opportunities. The firm’s current fund is over $300M and the firm is planning to raise a $200M fund focused on life sciences and consumer products. The firm’s minimum investment begins at $5M, and the investment size depends on the stage of the targeted company. The firm primarily invests in later stage life science companies. The firm is looking for companies in North America and Canada and would seek distribution rights in China. The firm is actively looking for investment opportunities and plans to make 4-5 new investments as soon as possible. The firm would only seek to be the lead investor and will request a board seat.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, and Healthcare IT companies. The firm is open to all kinds of therapeutic assets but prefers companies that are into phase I of clinical trials or later. The firm is especially interested in vaccines including flu vaccines, Hepatitis A vaccine, Hepatitis B vaccine, and any other drugs for common diseases in China. The firm has a strong preference for later stage companies with products and pipelines that can directly produce and sell in China. The firm is open to medical devices with all FDA regulatory pathways, including 510k, PMA, and software-enabled devices. The firm is open to any phases in medical devices and therapeutics with a preference for those within human data. The most important consideration is the potential market in China.

The firm considers the management team’s character and entrepreneurial spirit. Team members who speak Mandarin may be a plus but is not required.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture capital arm of a global generic manufacturer has headquarters in Western Europe. The firm can invest $200K-$5M to a round. The firm will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. They are open to working with companies globally.

Within digital health, the firm is seeking companies that are in the prevention and adherence space as well as digital medical devices and big data analytics platforms that address chronic diseases (Diabetes, Obesity and Cardiovascular), respiratory diseases, oncology, consumer and mental health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with management teams with a track record in the space and a strong business plan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in the Greater China region has over US $300 billion in total customer assets and operations in 24 countries and has developed a broad footprint across Asia since establishment. The firm specializes in green-field, early and growth stage investments. With an evergreen fund structure, the firm can be flexible in terms of investment sizes (up to $250 million per deal) and horizon. The firm typically makes equity investments and works with businesses based in China or with a China angle.

Within life sciences, the firm works on a wide range of technology sectors including therapeutics, medical devices, diagnostics, biotech R&D services, healthcare IT, and healthcare services. The firm is very opportunistic in terms of subsectors and indications but historically has been active in biosimilars and biotech R&D. The firm evaluates technologies based on two main criteria: meaningful impact on human health; bold and innovative ideas. The firm has no specific preference in the investment stage. However, the firm generally invests in earlier stage for therapeutics and R&D and later stage for medical devices, but seeds have been done with exceptional founding teams.

The firm is seeking companies with a strong and experienced management team. The firm is flexible when it comes to post-investment board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm and investment fund utilizing the virtual pharma (‘asset-centric’) model  invests in early stage pharmaceutical assets (i.e., small molecules and biologics, including cell or gene therapies), and provides up to $25 million, or more, to fund each project, typically through Phase 2 clinical proof-of-concept, before exiting through sales of successful assets to major pharmaceutical companies.

The firm prefers to in-license or acquire individual pharmaceutical assets through innovative deal structures that keep the founders and company involved and leading the development of their assets, and is less likely to make traditional equity investments in companies. Ideal candidates have yet to receive significant VC funding, and the firm prefers to invest without typical syndicates. The firm integrates each company’s founders and their asset(s) into its own special purpose vehicle and collaborates closely with them — providing broad and deep drug development expertise and resources to maximize product value. The firm invests in projects around the globe and aims to maintain a portfolio of 15-20 high quality investments.

The firm seeks biopharmaceutical drug assets — small molecules, biologics, and cell or gene therapies. The firm is willing to invest in drug candidates that are up to 12-18 months pre-IND, as well as those that are in, or have completed, Phase I clinical trial(s). Ideal candidates are ‘IND-ready’, patent-protected in all major pharma markets, and represent both potential solutions to unmet medical need and significant market potential. The firm is open to all therapeutic areas and indications for which proof-of-concept can be evaluated in early clinical trials.

The firm is looking to partner with founders and associates with a deep understanding of the science and pharmacology underlying their product, and who are willing to operate in a highly collaborative, virtual and global environment. Such willingness to collaborate is essential because the firm acts as a hands-on investor and partner — contributing its extensive drug development expertise and operational resources to each company’s asset(s) to ensure that all assets are developed in the most efficient and effective manner, with a particular focus on early development de-risking.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.